A novel low-fired NaCaLa(MoO
4
)
3
ceramic was synthesized via a conventional solid-state reaction method. The sintering behavior, phase structure, morphology, and microwave dielectric properties of ...ceramic were systematically investigated. NaCaLa(MoO
4
)
3
compound was confirmed to be a single-phase with a tetragonal scheelite structure of
I4
1
/a
space group. The sintering temperature will affect the cationic ordering of NaCaLa(MoO
4
)
3
ceramics, thereby affecting the quality factor. NaCaLa(MoO
4
)
3
ceramics exhibited a high relative density above 98% in the all sintering ranges, especially the maximum relative density reached 98.34%. The theoretical dielectric constant and packing fraction were calculated based on the refined parameters. The calculations for the chemical bonds of NaCaLa(MoO
4
)
3
ceramics show that NaCaLa–O bond and Mo–O bond have the upper hand in dielectric constant and quality factor, respectively. NaCaLa(MoO
4
)
3
ceramic sintered at 825 °C demonstrates foremost microwave dielectric properties with low
ε
r
= 10.72, high
Q
×
f
= 49,495 GHz, and
τ
f
=
−
49 ppm/
°
C. Momentously, NaCaLa(MoO
4
)
3
ceramic had a good compatibility with Ag powder, suggesting that it is a potential candidate for LTCC applications.
Full text
Available for:
EMUNI, FIS, FZAB, GEOZS, GIS, IJS, IMTLJ, KILJ, KISLJ, MFDPS, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, SBMB, SBNM, UKNU, UL, UM, UPUK, VKSCE, ZAGLJ
•A novel Vibrio cyclitrophicus phage vB_VviC_ZQ26 was isolated from the coastal water of Qingdao, China (120.327°E, 36.065°N).•Phage vB_VviC_ZQ26 represents a new family-level cluster, named ...Coheviridae, within the Caudoviricetes.•Two gene transfer agent proteins are encoded by phage vB_VviC_ZQ26, including baseplate attachment domain and central domain.•Phage vB_VviC_ZQ26 has a low relative abundance in the marine environment but one of the family members has high abundance.
Vibrio is a prevalent bacterial genus in aquatic environments and exhibits diverse metabolic capabilities, playing a vital role in marine biogeochemical cycles. This study isolated a novel virus infecting Vibrio cyclitrophicus, vB_VviC_ZQ26, from coastal waters near Qingdao, China. The vB_VviC_ZQ26 comprises a linear double-stranded DNA genome with a length of 42,982 bp and a G + C content of 43.21 %, encoding 72 putative open reading frames (ORFs). Transmission electron microscope characterization indicates a siphoviral-morphology of vB_VviC_ZQ26. Nucleic-acids-wide analysis indicates a tetranucleotide frequency deviation for genomic segments encoding putative gene transfer agent protein (GTA) and coil-containing protein, implying divergent origins occurred in different parts of viral genomes. Phylogenetic and genome-content-based analysis suggest that vB_VviC_ZQ26 represents a novel vibriophage-specific family designated as Coheviridae. From the result of biogeographic analysis, Coheviridae is mainly colonized in the temperate and tropical epipelagic zones. This study describes a novel vibriophage infecting V. cyclitrophicus, shedding light on the evolutionary divergence of different parts of the viral genome and its ecological footprint in marine environments.
Full text
Available for:
GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP
Highlights
A comprehensive summary of the representative promising applications of metal halide perovskite materials, including traditional optoelectronic devices (solar cells, light-emitting diodes, ...photodetectors, lasers), and cutting-edge technologies in terms of neuromorphic devices (artificial synapses and memristors) and pressure-induced emission.
For each application, the fundamentals of the field, the current progress and the remaining challenges are provided, based on the up-to-date works.
Nowadays, the soar of photovoltaic performance of perovskite solar cells has set off a fever in the study of metal halide perovskite materials. The excellent optoelectronic properties and defect tolerance feature allow metal halide perovskite to be employed in a wide variety of applications. This article provides a holistic review over the current progress and future prospects of metal halide perovskite materials in representative promising applications, including traditional optoelectronic devices (solar cells, light-emitting diodes, photodetectors, lasers), and cutting-edge technologies in terms of neuromorphic devices (artificial synapses and memristors) and pressure-induced emission. This review highlights the fundamentals, the current progress and the remaining challenges for each application, aiming to provide a comprehensive overview of the development status and a navigation of future research for metal halide perovskite materials and devices.
Full text
Available for:
IZUM, KILJ, NUK, PILJ, PNG, SAZU, UL, UM, UPUK
Limited to inadequate stem-cell doses, cord blood transplantation (UCBT) is accompanied by increased graft failure and delayed haematopoietic recovery. The conditioning regimen is critically ...important for engraftment, and numerous trials have been undertaken comparing the outcomes of IV Bu and TBI, but there are no comparative data for UCBT. We conducted a retrospective multicentre study to analyse the outcomes of IV Bu and TBI in UCBT patients with haematologic malignancies. Between 1 May, 2008 and 31 Mar, 31 2018, a total of 331 patients from the China Umbilical Cord Blood Transplantation Corporation (IV Bu, n = 131; TBI, n = 200) were evaluated. The cumulative incidence of neutrophil engraftment was 91.6% in the IV Bu/Cy cohort and 98.0% in the Cy/TBI cohort (P < 0.001). The median times to neutrophil engraftment were 16 and 19 days (P < 0.001), respectively. Multivariate analysis showed no statistical difference for nonrelapse mortality (hazard ratio HR, 1.11; 95% confidence interval CI, 0.66 to 1.86; P = 0.695), relapse (HR, 0.90; 95% CI, 0.50 to 1.60; P = 0.713) and overall survival (HR, 0.94; 95% CI, 0.61 to 1.44; P = 0.763) between the two conditioning regimens. Our results show that both IV Bu and TBI are valid myeloablative conditioning regimens for haematologic malignancy patients treated with UCBT.
Full text
Available for:
EMUNI, FIS, FZAB, GEOZS, GIS, IJS, IMTLJ, KILJ, KISLJ, MFDPS, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, SBMB, SBNM, UKNU, UL, UM, UPUK, VKSCE, ZAGLJ
•A novel Stutzerimonas stutzeri phage vB_PstM_ZRG1 was isolated from the East China Sea.•Phage vB_PstM_ZRG1 represents a new genus-level cluster, named Elithevirus, within the Caudoviricetes.•Three ...AMGs are encoded by phage vB_PstM_ZRG1, including TIR domain, PAAR protein and SGNH family hydrolase.•Phage vB_PstM_ZRG1 has a low relative abundance in the marine environment but is capable of infecting widely distributed hosts.
Stutzerimonas stutzeri is an opportunistic pathogen widely distributed in the environment and displays diverse metabolic capabilities. In this study, a novel lytic S. stutzeri phage, named vB_PstM_ZRG1, was isolated from the seawater in the East China Sea (29°09’N, 123°39’E). vB_PstM_ZRG1 was stable at temperatures ranging from -20°C to 65°C and across a wide range of pH values from 3 to 10. The genome of vB_PstM_ZRG1 was determined to be a double-stranded DNA with a genome size of 52,767 bp, containing 78 putative open reading frames (ORFs). Three auxiliary metabolic genes encoded by phage vB_PstM_ZRG1 were predicted, including Toll/interleukin-1 receptor (TIR) domain, proline-alanine-alanine-arginine (PAAR) protein and SGNH (Ser-Gly-Asn-His) family hydrolase, especially TIR domain is not common in isolated phages. Phylogenic and network analysis showed that vB_PstM_ZRG1 has low similarity to other phage genomes in the GenBank and IMG/VR database, and might represent a novel viral genus, named Elithevirus. Additionally, the distribution map results indicated that vB_PstM_ZRG1 could infect both extreme colds- and warm-type hosts in the marine environment. In summary, our finding provided basic information for further research on the relationship between S. stutzeri and their phages, and expanded our understanding of genomic characteristics, phylogenetic diversity and distribution of Elithevirus.
Full text
Available for:
GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP
Display omitted
•Rough and smooth Pt shells were obtained by two dealloying methods.•Rough-NPs are more MA towards CH3OH, but the Cu is easily over-dissolved.•Smooth-NPs are less MA towards methanol, ...but Cu is more difficult to dissolve.•The MA of smooth-NPs is enhanced by the slight structural evolution of the surface.•The PtM i-NPs composed of different M (M = Mn, Fe, Cu, and Zn) have the similar conclusion.
An accurate understanding of the surface structure–activity relationship is essential to rational designing highly efficient electrocatalysts for methanol oxidation reaction (MOR). Here, L11-ordered PtCu/C with rough and smooth Pt shells were obtained by electrochemically (ED) and chemically dealloying (CD) methods to investigate the difference in their MOR performances. The rough Pt shells (PtCu/C-700-ED) exhibited mass activity (MA) of 1625.2 mA mgPt−1 at peak potential, 2.19 and 2.74 times higher than smooth Pt shells (PtCu/C-700-CD) (743.1 mA mgPt−1) and commercial Pt/C (593.5 mA mgPt−1), respectively. DFT calculations indicate that PtCu with rough surfaces has a weaker CO binding energy than that with smooth surfaces, leading to better CO resistance and MOR activity. However, accelerated durability tests exhibit that the PtCu/C-700-CD catalysts obtained activity above the initial current density after 2000 cycles compared to PtCu/C-700-ED (36.48% loss) and commercial Pt/C (67.35% loss), indicating that smooth Pt shells have prominent structural stability. In addition, similar results were found simultaneously for other ordered Pt-based binary catalysts.
Full text
Available for:
GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP
The stepped micro-mirror imaging Fourier transform spectrometer (SIFTS) has the advantages of high throughput, compactness, and stability. However, the systematic errors in the interference core of ...the SIFTS have a significant impact on the interferogram and the reconstructed spectrum. In order to reduce the influence of systematic errors, a transfer error model of the systematic errors in the interference core of the SIFTS is established, and an interferogram and spectrum calibration method is presented, which combines the least squares fitting calibration and the row-by-row fast Fourier transform-inverse fast Fourier transform (FFT-IFFT) flat-field calibration. The experimental results show that the methods can sufficiently reduce the influence of systematic errors in the interference core of the SIFTS, such as the interferogram fringe tilt, the peak position shift of the reconstructed spectrum, and the error of spectral response.
Full text
Available for:
IZUM, KILJ, NUK, PILJ, PNG, SAZU, UL, UM, UPUK
Introduction: Orelabrutinib is a second-generation Bruton tyrosine kinase inhibitor (BTKi) with high kinase selectivity. Clinical studies have demonstrated that orelabrutinib achieved a high complete ...response rate of 26.3% in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), showing promising efficacy and acceptable safety profile. However, the real-world data of Orelabrutinib are not available. This study aimed to evaluate the effectiveness and safety of orelabrutinib-containing regimens for the treatment of patients (pts) with CLL/SLL in a real-world setting. Methods: This was a retrospective, multi-center, real-world study conducted. Pts (aged 18 years or older) with CLL/SLL who received at least 3 months of orelabrutinib-containing regimens between December 2020 and March 2023 were analyzed. Efficacy was evaluated by hematologic response rate (HRR), defined as the proportion of pts who met at least 1 of the following hematologic response criteria: hemoglobin response (pts having a recovery of hemoglobin value or ≥50% increase from baseline), platelet response (pts having a recovery of platelet count or ≥50% increase from baseline), or lymphocyte response (pts having a recovery of lymphocyte count or ≥50% reduction from baseline). Safety was assessed by adverse events (AEs) as per NCI-CTCAE 5.0. Results: 24 pts with CLL/SLL (12 males; 22 CLL) were included, with a median age of 62.5 years (range: 38-82). Most pts had an Eastern Cooperative Oncology Group score of 0-1 (17/24, 70.8%) and Rai stage III or IV disease (16/18, 88.9%). 7 pts with hypertension, of which 2 with very high-risk hypertension. 3 pts have previously received other BTKi. A total of 9 pts(37.5%) performed del(17p), TP53, or IGHV testing. Among them, pts received orelabrutinib 100 mg (2/24,) or 150 mg (22/24,) once daily. As of the cut-off date (July 13, 2023), the median follow-up was 10.67 (range, 2.73-25.77) months. 18 pts (16 CLL, 2 SLL) with abnormal hemoglobin value, platelet count, or lymphocyte count at baseline were evaluable for hematologic response. Hematologic response was achieved in 11 (61.1%) of 18 evaluable pts. Pts aged <65 years had a higher HRR versus pts aged ≥65 years (87.5% vs. 40.0%, p=0.040). HRR was 56.3% in CLL versus 100.0% in SLL pts, and 60.0% in pts with hypertension versus 61.5% without hypertension . Four of 11 responders had a hematologic response in at least two criteria (CLL, n=3; SLL, n=1), of which 3 pts had a hemoglobin response (Figure 1). The most commonly reported AEs included hemoglobin decreased (16.7%) and platelet count decreased (16.7%). Grade ≥3 AEs were white blood cell count decreased (4.2%), platelet count decreased (4.2%), and lymphocyte count decreased (4.2%). No pts experienced severe AEs. No cardiovascular AEs were reported during treatment in 7 pts with hypertension at baseline. Conclusions: This real-world study assessed the preliminary characteristics and clinical outcome of patients receiving orelabrutinib-containing regimens under routine clinical practice conditions in China. The orelabrutinib-containing regimens in this study furnished beneficial evidence for the treatment of CLL/SLL and is essential for determining the best treatment option, future data with a larger sample and longer follow-up will be updated.
Full text
Available for:
IJS, IMTLJ, KILJ, NLZOH, NUK, SAZU, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP
PDF
